Valneva initiated pivotal phase 3 clinical trial for inactivated, COVID-19 vaccine using Dynavax’s CpG 1018ル adjuvant
On Apr. 21, 2021, Dynavax Technologies announced Valneva had initiated a pivotal Phase 3 clinical trial for its…
On Apr. 21, 2021, Dynavax Technologies announced Valneva had initiated a pivotal Phase 3 clinical trial for its…
On Apr. 21, 2021, the NIH announced that a Phase 2/3 trial to evaluate a new fully-human polyclonal…
On Apr. 20, 2021, the University of Oxford, Prenetics, and Oxford Suzhou Centre for Advanced Research announced that…
On Apr. 19, 2021, Resverlogix announced the publishing of an article titled: モBromodomain and extraterminal protein inhibitor, apabetalone…
On Apr. 19, 2021, Tonix Pharmaceuticals and OyaGen announced an exclusive worldwide licensing agreement for an antiviral inhibitor…
On Apr. 16, 2021, the FDA revoked the emergency use authorization (EUA) that allowed for Eli Lilly’s investigational…
On Apr. 15, 2021, researchers at the University of Oxford reported that the risk of the rare blood…
On Apr. 15, 2021, the National Institutes of Health announced that the experimental antiviral drug MK-4482 significantly decreased…
On Apr. 15, 2021, Inovio Pharmaceuticals announced the results of a study focusing on the human immune responses…
On Apr. 15, 2021, CytoDyn announced it had executed an exclusive supply and distribution agreement with Chiral Pharma…
On Apr. 13, 2021, a clinical trial testing the safety and efficacy of an investigational monoclonal antibody for…
On Apr. 13, 2021, Moderna announced clinical and supply updates on its COVID-19 Vaccine program. New results from…
On Apr. 12, 2021, Roche confirmed positive results from the phase III REGN-COV 2069 trial assessing the ability…
On Apr. 12, 2021, Resverlogix announced that it had successfully received its desired ‘No Objection Letter’ from Health…
On Apr. 9, 2021, the Broad Institute of MIT in partnership with the Centers for Disease Control and…
On Apr. 9, 2021, Regeneron announced that newly updated National Institutes of Health (NIH) COVID-19 Treatment Guidelines strongly recommend…
On Apr. 9, 2021, Pfizer announced they had requested amendments to the U.S. Emergency Use Authorization (EUA) of…
On Apr. 8, 2021, Oxford University announced that favipiravir was to be investigated in the UK as part…
On Apr. 7, 2021, the National Institutes of Health (NIH) announced that a clinical trial is underway to determine…
On Apr. 7, 2021, Moderna announced publication of antibody persistence data out to 6 months following the second…
On Apr. 7, 2021, the Centers for Disease Control and Prevention (CDC) announced it has awarded funding to support…
On Apr. 6, 2021, Moderna and Catalent announced the expansion of their strategic collaboration to dedicate a new…
On Apr. 5, 2021, Anixa Biosciences announced that based on Proof of Concept animal study results, it was…
On Apr. 5, 2021, Novavax announced the initiation of crossover arms in two ongoing clinical trials of NVX-CoV2373,…
On Apr. 4, 2021, Emergent BioSolutions announced it had received a contract modification to increase the original task…
On Apr. 2, 2021, Emergent BioSolutions announced that topline data from the ITAC trial had demonstrated that the…
On Apr. 1, 2021, Kaiser Permanente Washington Health Research Institute (KPWHRI) announced that an investigational vaccine designed to…
On Apr. 1, 2021, the U.S. Food and Drug Administration (FDA) announced two revisions regarding the number of…
On Apr. 1, 2021, BD (Becton, Dickinson) announced the U.S. Food and Drug Administration (FDA) had granted Emergency…
On Apr. 1, 2021, Arbutus Biopharma, X-Chem and Proteros Biostructures announced hat they had entered into a discovery…